Aktie A3CUPH BIOMEA FUSION, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Biomea Fusion, Inc.

Aktien

A3CUPH

US09077A1060

BMEA

Realtime-Estimate Cboe BZX
Andere Börsenplätze
 20:58:56 10.05.2024 		% 5 Tage % 1. Jan.
10,74 USD -6,08 % Intraday Chart für Biomea Fusion, Inc. -12,71 % -25,76 %
02.05. Biomea Fusion, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
02.04. Biomea Fusion-Aktien fallen nach Herabstufung durch JPMorgan MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
North American Morning Briefing : Powell Awaited -2-
Biomea Fusion Shares Decline Following JPMorgan Downgrade
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Tech in Focus on -2-
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study with BMF-219
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CUPH Aktie
  4. Nachrichten Biomea Fusion, Inc.
  5. Andere Sprachen